Key Takeaways
- CMS approved a final 2.48% rate hike for Medicare Advantage in 2027, dramatically exceeding the 0.09% preliminary rate announced in January.
- Humana (HUM) shares skyrocketed 12% in after-hours trading, while UnitedHealth (UNH) and CVS Health (CVS) climbed over 6% before the bell.
- The approved rate boost injects approximately $13 billion in extra Medicare Advantage reimbursements to health insurers for 2027.
- Rival health plans and hospital operators also gained, including Molina Healthcare (MOH) up 7% and Centene (CNC) advancing 4%.
- Mizuho’s Jared Holz noted the rate represents a significant improvement over the preliminary figure, though cautioned it’s “not so awesome in a vacuum.”
Humana (HUM) shares climbed approximately 11% at Tuesday’s opening bell after regulators unveiled the finalized 2027 Medicare Advantage reimbursement rates on Monday evening.
The approved 2.48% increase represents a substantial upgrade from the preliminary 0.09% figure floated in January, which had blindsided the healthcare sector and triggered sell-offs in insurance stocks.
According to the CMS disclosure, private health insurers stand to receive over $13 billion in incremental Medicare Advantage funding from federal coffers during 2027.
UnitedHealth (UNH) and CVS Health (CVS), which operates Aetna, each surged more than 6% during premarket hours Tuesday. Elevance Health (ELV) advanced roughly 5%. Healthcare providers and managed care operators also benefited, with Molina Healthcare (MOH) jumping 7% and Centene (CNC) gaining 4%.
The equity rally followed intensive advocacy efforts by insurance companies and industry associations throughout recent months, arguing that January’s proposal ignored escalating healthcare expenditures. The Better Medicare Alliance characterized the initial near-zero rate as effectively a “reduction,” highlighting that medical cost inflation has been running between 7% and 9% year-over-year.
Technical Adjustments in Final Rules
Beyond the headline percentage, CMS implemented multiple technical modifications. Beginning in 2027, regulators will eliminate diagnosis information derived from unlinked chart review documentation when computing risk scores, though beneficiaries transitioning between Medicare Advantage carriers receive an exemption.
Regulators indicated this policy shift will disproportionately affect plans that depend extensively on such chart documentation to validate patient diagnoses and secure enhanced reimbursement. CMS additionally revised the Part D risk adjustment framework to incorporate Inflation Reduction Act provisions.
CMS Administrator Dr. Mehmet Oz stated the modifications seek to maintain “coverage affordable” while ensuring enrollees receive “real value from their plans.”
Financial analysts had maintained conservative expectations before Monday’s release. TD Cowen’s Ryan Langston had projected a relatively modest increase between 1% and 1.5%. The 2.48% result surpassed these forecasts, although Mizuho’s Jared Holz offered measured optimism: “We do not believe a Medicare rate increase of 2.5% is so awesome in a vacuum, but is certainly better than the government’s initial rate decision.”
Holz suggested there now exists “a chance for margins to expand next year, provided the Companies continue to trim benefits and align costs with revenue.”
Industry Implications
Medicare Advantage provides coverage to approximately 35 million Americans and has experienced consistent expansion, now exceeding enrollment figures in traditional fee-for-service Medicare. The finalized rate determines the allocation of more than half a trillion dollars through private insurance plans annually, positioning it among the most scrutinized metrics within the health insurance industry.
The calculation incorporates multiple variables including projected cost inflation, 2026 Star Ratings determining quality incentive payments, and risk adjustment formula refinements. CMS verified it will maintain the 2024 Medicare Advantage risk adjustment framework for 2027.
Bipartisan congressional concerns regarding Medicare Advantage expenditures had injected additional uncertainty into the rate-setting cycle. Lawmakers from both parties have questioned insurer diagnostic coding methodologies that can generate elevated payments for patients with more documented conditions. The Biden administration’s CMS had already begun constraining these reimbursements, and January’s preliminary proposal under the Trump administration indicated ongoing regulatory vigilance.
